Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Uni-Bio Science Group Ltd

UNBSF:PKC

Uni-Bio Science Group Ltd

Actions
  • Price (USD)0.004
  • Today's Change0.00 / 0.00%
  • Shares traded3.20k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 25 2024 18:39 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Uni-Bio Science Group Limited is a Hong Kong-based investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.

  • Revenue in HKD (TTM)508.40m
  • Net income in HKD98.86m
  • Incorporated2001
  • Employees458.00
  • Location
    Uni-Bio Science Group Ltd13/F, Public Bank Centre,120 Des Voeux Road Central, Central Hong KongHKG
  • Phone+852 31023232
  • Fax+852 31023737
  • Websitehttps://www.uni-bioscience.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.